European Medicines Agency
Impurity found in valsartan manufactured by second company in China, EMA says
Low levels of the potentially harmful impurity N-nitrosodimethylamine (NDMA) have been , the European Medicines Agency (EMA) has learnt.
Originally, NDMA was found in the active substance manufactured by Chinese pharmaceutical company Zhejiang Huahai Pharmaceutical, but now the impurity has been detected in valsartan manufactured by another Chinese company, Zhejiang Tianyu Pharmaceutical.
However, the NDMA levels detected in batches of valsartan from Zhejiang Tianyu are much lower than levels seen in the active substance from Zhejiang Huahai, which triggered a recall of several valsartan medicines in July 2018.
The EMA said it is working closely with international partners to review the impact of the NDMA detected in valsartan manufactured by Zhejiang Tianyu and will communicate its findings as soon as possible.
According to the EMA, there is “no immediate risk to patients” and “patients should not stop taking any valsartan medicines without consulting their doctor or pharmacist”.
Citation: Electronicjuice DOI: 10.1211/PJ.2018.20205317
Recommended from Pharmaceutical Press
Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.£22.00
A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.£38.00
A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.£38.00
A practical reference source on alternative and complementary therapies. Enables healthcare professionals to give knowledge-based advice.£43.00
A study aid with 800 MCQs. Assess your knowledge, analytical skills, and ability to apply this knowledge base in clinical practice.£25.00